<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03484754</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A0392-51</org_study_id>
    <nct_id>NCT03484754</nct_id>
  </id_info>
  <brief_title>Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites.</brief_title>
  <acronym>OnaDEP</acronym>
  <official_title>Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites at Three Months.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Esquirol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Esquirol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate in adult subjects with resistant depression the effect of&#xD;
      an injection of botulinum toxin in the corrugator and procerus muscles, in comparison to the&#xD;
      infiltration of the crow's feet area, in addition to the current antidepressant treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three randomized, double-blind, placebo-controlled studies have shown that a single injection&#xD;
      of OnaBotulinum Toxin A (OnaA) into the corrugator and procerus (frowning muscles) allows for&#xD;
      a significant decrease in patients with a depressive episode characterized resistant.&#xD;
&#xD;
      However, the effectiveness of this method of treating depression can not currently be&#xD;
      considered established.&#xD;
&#xD;
      The main objective of our study is therefore to evaluate the efficacy of OnaA injections in&#xD;
      the glabellar zone with a different methodology, using lateral muscle injection orbicularis&#xD;
      oculi (involved in crow's feet wrinkles). ) as another injection zone in comparison.&#xD;
&#xD;
      The efficacy will correspond to the number of responders at 6 weeks in the two groups of&#xD;
      injection.&#xD;
&#xD;
      This evaluation will be done at 6 weeks, then at 3 months (S12).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The main pitfall of these studies is indeed the difficulty in ensuring a double-blind when the TB is injected into the corrugator and the procerus with placebo as physiological saline, since the patient as the examiner can guess which product was administered.&#xD;
The main objective of our study is therefore to evaluate the efficacy of OnaA injections in the glabellar zone , using lateral muscle injection orbicularis oculi (involved in crow's feet wrinkles) as another injection zone in comparison.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>blinding impossible</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with improvement of depressive symptoms based on the evolution of the MADRS scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>≥ 50% decrease from baseline of the MADRS score will be considered as improvement (Montgomery and Asberg depression rating scale - total score = 60 points for maximum depression)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>corrugator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single injection of 10 Units of botulinum toxina in the corrugator and procerus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>orbicularis oculi</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin</intervention_name>
    <description>injection of botulinum toxina in two different facial sites</description>
    <arm_group_label>corrugator</arm_group_label>
    <arm_group_label>orbicularis oculi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female from 18 to 80 years old included&#xD;
&#xD;
          -  Inpatient or ambulatory patients treated for resistant depressive episode, that is to&#xD;
             say by an absence of symptomatic remission (nonresponse or partial response) after the&#xD;
             use of two successive trials of antidepressants of different pharmacological class,&#xD;
             well conducted in terms of dosage and duration, while ensuring quality adherence (at&#xD;
             least 80% of the treatment taken during the period considered)&#xD;
&#xD;
          -  Diagnosis according to DSM-5 depressive episode characterized with MADRS score&gt; 20&#xD;
&#xD;
          -  Women of childbearing potential must have an effective method of contraception&#xD;
             (failure rate &lt;1% per year with correct use): IUD, pill, ... (participant statement)&#xD;
&#xD;
          -  Patient able to adhere to the restrictions and prohibitions of the protocol&#xD;
&#xD;
          -  Patient agreeing to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current psychiatric comorbidity&#xD;
&#xD;
          -  Severe intellectual disability&#xD;
&#xD;
          -  Known hypersensitivity to botulinum toxin type A or any of the excipients&#xD;
&#xD;
          -  Myasthenia gravis&#xD;
&#xD;
          -  Presence of infection at the injection site (s)&#xD;
&#xD;
          -  Participation in an interventional clinical study.&#xD;
&#xD;
          -  Pregnant woman, breastfeeding, or who plans to be pregnant during the study or within&#xD;
             6 weeks after the last administration of the treatment.&#xD;
&#xD;
          -  Any patient already receiving aesthetic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Charles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Esquirol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danièle Ranoux, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier esquirol</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Esquirol</investigator_affiliation>
    <investigator_full_name>Eric Charles</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

